Search results
Results From The WOW.Com Content Network
Chelation therapy is a medical procedure that involves the administration of chelating agents to remove heavy metals from the body. [1] Chelation therapy has a long history of use in clinical toxicology [2] and remains in use for some very specific medical treatments, although it is administered under very careful medical supervision due to various inherent risks, including the mobilization of ...
Ethylenediaminetetraacetic acid (EDTA), also called EDTA acid, is an aminopolycarboxylic acid with the formula [CH 2 N(CH 2 CO 2 H) 2] 2. This white, slightly water-soluble solid is widely used to bind to iron (Fe 2+ /Fe 3+) and calcium ions (Ca 2+), forming water-soluble complexes even at neutral pH. It is thus used to dissolve Fe- and Ca ...
Sodium calcium edetate is in the chelating agent family of medication. [3] It is a salt of edetate with two sodium atoms and one calcium atom. [4] It works by binding to a number of heavy metals, which renders them almost inert and allows them to leave the body in the urine.
DOTA is derived from the macrocycle known as cyclen.The four secondary amine groups are modified by replacement of the N-H centers with N-CH 2 CO 2 H groups. The resulting aminopolycarboxylic acid, upon ionization of the carboxylic acid groups, is a high affinity chelating agent for di- and trivalent cations.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Although the concept and practical use of metal chelation is common, chelation of inert metals, such as platinum, has been rarely reported and the yield was extremely low. [2] To produce chelated platinum solution, tetraammonium EDTA , NTA, DTPA or HEDTA type chelating agent was mixed with platinum or platinum chemical compounds.
For example, the CHOP regimen consists of cyclophosphamide, doxorubicin, vincristine and prednisone. Besides chemotherapy, medical oncology (pharmacotherapy for cancer) includes several noncytotoxic classes of therapy, such as hormonal therapy and targeted therapy (biologic therapy). Those agents are described in the relevant articles.
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer